Submit a Release
Home
All
ESG
Health
Technology
Finance
Contributors
Sub Menu
Submit a Release
main-search-pop
Main menu
Théa Opens a New Chapter in Retinal Diseases
Contributed by:
Presswire
Tags
ophthalmology
Théa
More Like This
Sepul Bio, an innovative business unit of Théa, Doses First Participant in Phase 3 HYPERION clinical trial of sepofarsen for CEP290-associated Leber Congenital Amaurosis Type 10
Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)
Axovia Therapeutics Announces Three Upcoming Poster Presentations at ASGCT
Norgine strengthens rare disease portfolio with acquisition of Theravia
Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa
Institute of Molecular and Clinical Ophthalmology Basel Spinout RhyGaze Closes USD 86 Million Series A Round to Further Novel Gene Therapy for Vision Restoration
Department of Health - Abu Dhabi and Opus Genetics Announce Collaboration to Advance Ground-Breaking Gene Therapy Research for Inherited Retinal Diseases
LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision
